Epiomic Epidemiology Series: Essential Thrombocythemia Forecast in 9 Major Markets 2016-2026

March 2016 | 40 pages | ID: E8DB6EE23C5EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Age-related Macular Degeneration (AMD) Disease in 7 Major Markets

Age-related macular degeneration (AMD or ARMD) or Age-related Maculopathy (ARM) is a condition that involves the degeneration and damage to the central area of the retina – the macula. It is currently a common cause of visual impairment in Western Europe. AMD is typically painless, and the loss of central vision usually occurs in both eyes but may progress at different speeds.

This report provides the current prevalent population for AMD across 7 Major Markets (USA, France, Germany, Italy, Spain, UK and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AMD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AMD include:

• Serous retinal detachment
• Haemorrhage
• Charles Bonnet Syndrome
• Depression
• Reduced quality of life
• Hypertension
• Hypercholesterolaemia (abdominal obesity is a specific risk factor for males)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global AMD’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of AMD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on AMD’s prevalent population.
• Identify sub-populations within AMD which require treatment.
• Gain an understanding of the specific markets that have the largest number of AMD patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Essential Thrombocythemia
Features of Essential Thrombocythemia Patients
  Type of Thrombotic Events
  Abnormal Organ Enlargement Associated with ET
  Blood Cell Associated Conditions
  Gene Mutations in ET
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

WHO classification criteria for ET diagnosis
Prevalence of Essential Thrombocythemia, total (000s)
Prevalence of Essential Thrombocythemia, males (000s)
Prevalence of Essential Thrombocythemia, females (000s)
Type of thrombosis in Essential Thrombocythemia patients, total (000s)
History of thrombotic event in Essential Thrombocythemia patients, total (000s)
Site of arterial thrombosis in Essential Thrombocythemia patients, total (000s)
Site of venous thrombosis in Essential Thrombocythemia patients, total (000s)
Prevalence of splenomegaly in Essential Thrombocythemia, total (000s)
Prevalence of hepatomegaly in Essential Thrombocythemia, total (000s)
Prevalence of myelofibrosis (SMF) in Essential Thrombocythemia, total (000s)
Prevalence of anaemia in Essential Thrombocythemia, total (000s)
Prevalence of JAK2 mutation in Essential Thrombocythemia patients, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
USA Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
France Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
France Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
Germany Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
Italy Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
Spain Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
UK Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
Brazil Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
Japan Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)
India Prevalence of Essential Thrombocythemia by 5-yr age cohort, males (000s)
India Prevalence of Essential Thrombocythemia by 5-yr age cohort, females (000s)